Perspective Therapeutics, INC

Perspective Therapeutics announced Q2 2026 financial results, detailing progress in its radiopharmaceutical pipeline, including VMT-NET and VMT01 programs, and maintaining a cash runway into late 2027.

Perspective Therapeutics, Inc. has updated its corporate presentation, detailing advancements in its next-generation radiopharmaceutical oncology treatments, including VMT--NET, VMT01, and PSV359.

Perspective Therapeutics, Inc. has updated its corporate presentation, detailing advancements in its radiopharmaceutical oncology portfolio, including data on VMT--NET and VMT01 trials.

Perspective Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Perspective Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its radiopharmaceutical programs and a strengthened financial position with cash runway into late 2027.

Perspective Therapeutics, Inc. shared preliminary financial data and an update on its clinical programs and manufacturing technologies at an analyst event.

Perspective Therapeutics reports significant progress in its radiopharmaceutical pipeline, with strong cash reserves extending funding into late 2027, alongside a substantial capital raise.

Perspective Therapeutics reported increased net losses in Q3 2025 due to significant investments in radiopharmaceutical R&D and manufacturing, while advancing multiple clinical programs.

Perspective Therapeutics reported a significant increase in net loss for Q2 2025, driven by expanded research and development activities for its radiopharmaceutical pipeline, while maintaining strong liquidity into late 2026.

Perspective Therapeutics reports its financial results for the first quarter of 2025, showcasing progress in its clinical trials and pipeline development.

Perspective Therapeutics' Q3 2024 filing reveals significant financial growth and strategic advancements in its alpha therapy programs, alongside the divestiture of its brachytherapy business.

Perspective Therapeutics reports a significant increase in cash reserves and advancements in its clinical trials for targeted alpha therapies in its Q2 2024 report.

Perspective Therapeutics, a radiopharmaceutical developer, reported significant R&D investment and clinical progress for its alpha-particle therapies, alongside a recent $175 million capital raise, despite continued net losses.

Perspective Therapeutics files an amendment to its 2024 Form 10-K solely to include the signed audit report from WithumSmith+Brown, PC, while also providing a comprehensive business update.

Perspective Therapeutics highlights clinical progress, manufacturing expansion, and strategic agreements in its 2024 annual report, positioning itself for future growth in the radiopharmaceutical market.

Perspective Therapeutics details its strategy for developing targeted alpha therapies for cancer, leveraging its proprietary platform and recent acquisitions.

Perspective Therapeutics Director Maria E Martinez was granted 50,000 stock options as part of her 2026 annual equity award.

Perspective Therapeutics Director Frank Morich was granted 50,000 stock options as his 2026 annual equity award, exercisable at $5.35 per share.

Perspective Therapeutics Director Robert F. Williamson III received an annual equity award of 50,000 stock options, vesting in March 2027.

Perspective Therapeutics Director Heidi Henson was granted 50,000 stock options as her 2026 annual equity award, vesting fully on March 2, 2027.

Perspective Therapeutics Director Lori A. Woods was granted 50,000 stock options as her 2026 annual equity award.

Perspective Therapeutics, Inc. CEO Johan M. Spoor received an annual equity award of 735,000 stock options with an exercise price of $5.35, vesting over four years.

Perspective Therapeutics, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting agenda, including director elections and executive compensation votes.

Perspective Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 28, 2025, outlining key proposals for voting.

Perspective Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on May 28, 2025, to vote on director elections, auditor ratification, and executive compensation.

Perspective Therapeutics, Inc. is holding its 2024 Annual Meeting of Stockholders on May 31, 2024, to vote on the election of directors, a proposed reverse stock split, ratification of the accounting firm, and approval of the equity incentive plan.

Perspective Therapeutics is asking stockholders to vote on key proposals including a reverse stock split and an amendment to their equity incentive plan at the upcoming annual meeting.

Several entities affiliated with Millennium Management have filed a Schedule 13G, confirming their beneficial ownership of Perspective Therapeutics, Inc. common stock.

State Street Corporation has reported beneficial ownership of 5.3% of Perspective Therapeutics Inc.'s common stock as of June 30, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 5.3% of Perspective Therapeutics, Inc. common stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, reporting beneficial ownership of 4,893,883 shares, or 4.3%, of Perspective Therapeutics, Inc. common stock.

Morgan Stanley has filed a Schedule 13G, reporting a beneficial ownership of 2.6% in Perspective Therapeutics, Inc. as of March 31, 2026, indicating a reduction in its holdings.

Morgan Stanley has reported a 6.0% beneficial ownership stake in Perspective Therapeutics, Inc., holding 4,461,893 shares of common stock.